17 November 2022

Alderaan Biotechnology presents latest developments in next generation anti-CD25 antibody at SITC Congress

Paris, France, November 2, 2022 – Alderaan Biotechnology, a preclinical stage biotech company focused on monoclonal antibody development for the treatment of cancer, today announces it will present the most recent development of its new antibody candidate ALD2510 at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting on November 8-12, 2022, in Boston (MA, USA). The poster will cover its promising preclinical results on tolerability and manufacturability, as well as the potential of the antibody in the treatment of gynecologic and breast cancers. To know more